

---

## FRANCESCA MAGNANI, PhD

---

### BREVETTI

**Mutated form of NADPH oxidases.** Mattevi A, Nenci S, Magnani F (2018).

WO/2018/014939

**Development of a peptide analogue that selectively binds to the Angiotensin II-type 2 receptor.** Magnani F, Tzakos AG (2012). WO/2013/091883

**Mutant G-protein coupled receptors and methods for selecting them.** Henderson R, Tate CG, Magnani F, Serrano-Vega MJ, Shibata Y, Warne AJ (2008). WO/2008/114020

### ARTICOLI SCIENTIFICI

Ceccon M, Millana Fananas E, Massari M, Mattevi A, **Magnani F**. Engineering stability in NADPH oxidases: a common strategy for enzyme production. *Mol Membr Biol.* 2018 Oct 11:1-28.

Iacovino LG, **Magnani F**, Binda C. The structure of monoamine oxidases: past, present, and future. *J Neural Transm (Vienna).* 2018 Aug 24.

**Magnani F\***, Nenci S, Millana Fananas E, Ceccon M, Romero E, Fraaije M, Mattevi A\*. Crystal structures and atomic model of NADPH oxidase. *PNAS.* 2017 Jun

Piano V, Nenci S, **Magnani F**, Aliverti A, Mattevi A. Recombinant human dihydroxyacetonephosphate acyl-transferase characterization as an integral monotopic membrane protein. *Biochem Biophys Res Commun.* 2016 Dec 2;481(1-2):51-58.

**Magnani F**, Serrano-Vega MJ, Shibata Y, Abdul-Hussein S, Lebon G, Miller-Gallacher J, Singhal A, Strege A, Thomas JA & Tate CG. A mutagenesis and screening strategy to generate optimally thermostabilized membrane proteins for structural studies. *Nat Prot.* 2016 Jul 28; 11: 1554–1571.

**Magnani F**, Pappas C, Magafa V, Cordopatis P, Ishiguro S, Ohta N, , Bonvin A, Bosnyak S, Jones ES, Gerotheranassis IP, Tamura M, Widdop RE, Tzakos A. Electronic Sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II. *ACS-Chem Biol.* 2014; 9(7):1420-5.

Laursen NS, **Magnani F**, Gottfredsen RH, Petersen SV, Andersen GR. Structure, function and control of complement C5 and its proteolytic fragments. *Curr Mol Med.* 2012; 12(8):1083-97.

Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, **Magnani F**, Tate CG, Weir M, Marshall FH. Structure of the Adenosine A(2A) Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. *Structure.* 2011;19(9):1283-93.

Shibata Y, White JF, Serrano-Vega MJ, **Magnani F**, Aloia AL, Grisshammer R and Tate CG. Thermostabilization of the neurotensin receptor NTS1. *J Mol Biol.* 2009; 390(2):262-77.

**Magnani F**, Shibata Y, Serrano-Vega MJ, Tate CG. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor. *PNAS* 2008; 105(31):10744-9.

Serrano-Vega MJ, **Magnani F**, Shibata Y, Tate CG. Conformational thermostabilization of the beta1-adrenergic receptor in a detergent-resistant form. *PNAS* 2008; 105(3): 877-82.

**Magnani F**, Tate CG, Wynne S, Williams C, Haase J. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. *J Biol Chem.* 2004; 279(37):38770-8.

Tate CG, Haase J, Baker C, Boorsma M, **Magnani F**, Vallis Y, Williams DC. Comparison of seven different heterologous protein expression systems for the production of the serotonin transporter. *Biochim Biophys Acta.* 2003; 1610(1):141-53.

Haase J, Killian AM, **Magnani F**, Williams DC. Regulation of the serotonin transporter by interacting proteins. *Biochem Soc Trans.* 2001; 29(Pt 6):722-8. Review.

Pozza M, Bettelli C, **Magnani F**, Mascia MT, Manzini E, Calza L. Is neuronal nitric oxide involved in adjuvant-induced joint inflammation? *Eur J Pharmacol.* 1998; 359(1):87-93.